Sandra E. Dunn
About Sandra E. Dunn
Sandra E. Dunn, CEO of Phoenix Molecular Designs, founded the company in 2012 and has over 27 years of experience in breast cancer research, focusing on developing novel therapeutics.
Sandra E. Dunn - Chief Executive Officer
Sandra E. Dunn serves as the Chief Executive Officer of Phoenix Molecular Designs, a company she founded in 2012. Under her leadership, the company aims to target triple-negative breast cancer (TNBC) through innovative research and development. With a focus on identifying specific molecular targets, Dunn spearheads efforts to advance new cancer therapeutics. Her role as CEO encompasses strategic planning, fundraising, and driving the overall vision of the organization.
Sandra E. Dunn - Breast Cancer Researcher
Sandra E. Dunn has dedicated over 27 years to breast cancer research. Early in her career, Dunn was recognized for her commitment as a postdoctoral fellow at the National Institutes of Health. She identified RSK as a prime target for TNBC through functional genomic screens conducted in her laboratory. Her work has significantly contributed to understanding the molecular underpinnings of breast cancer and has driven advancements in targeted cancer therapies.
Sandra E. Dunn - Oversight Committee Involvement
Sandra E. Dunn has served on multiple oversight committees related to breast cancer research, including the Canadian Breast Cancer Foundation, the Department of Defense Breast Cancer Research Program (USA), and the Susan Komen Foundation. Early in her career, she was the youngest member of the DOD Breast Cancer Research Program in the early 1990s. Her participation in these committees highlights her extensive experience and commitment to guiding impactful breast cancer research.
Sandra E. Dunn - Industry, Government, and Academia Experience
Sandra E. Dunn has a broad range of experience spanning private industry, government, and academia. She has led multinational oncology research projects aimed at developing novel cancer therapeutics. Throughout her career, Dunn has forged close collaborations across various sectors, bolstering her approach towards integrated cancer research. Her efforts have included raising millions of dollars to fund innovative cancer research initiatives.
Sandra E. Dunn - Female-Led Biotechnology Company
Sandra E. Dunn built one of the few female-led biotechnology companies specifically aimed at eradicating breast cancer. Her leadership at Phoenix Molecular Designs exemplifies the power of female leadership in the biotech field. Driven by personal family experiences with cancer, Dunn's focus remains on making a tangible difference in the lives of individuals afflicted with breast cancer. Her company continues to pursue groundbreaking research to address unmet needs in cancer treatment.